Clene (CLNNW) Debt-to-Asset : 0.72 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Clene Debt-to-Asset?

Clene's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $20.64 Mil. Clene's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $11.81 Mil. Clene's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was $45.07 Mil. Clene's debt to asset for the quarter that ended in Mar. 2024 was 0.72.

Clene Debt-to-Asset Historical Data

The historical data trend for Clene's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clene Debt-to-Asset Chart

Clene Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

0.19

0.06

0.38

0.72

0.61

Clene Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial													0.81	0.47	0.53	0.61	0.72

Competitive Comparison of Clene's Debt-to-Asset

For the Biotechnology subindustry, Clene's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clene's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clene's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Clene's Debt-to-Asset falls into.

Clene Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Clene's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(20.106	+	12.055)	/	52.341
	=	0.61

Clene's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(20.635	+	11.805)	/	45.069
	=	0.72

Clene (NAS:CLNNW) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Clene Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Clene's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Clene (CLNNW) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clene Inc (NAS:CLNNW) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

CLNN:USA 84C:Germany

Address

6550 South Millrock Drive, Suite G50, Salt Lake City, UT, USA, 84121

Website

https://www.clene.com

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. Its reportable segments: (1) the development and commercialization of novel clean-surfaced nanotechnology therapeutics (Drugs, and (2) the development and commercialization of dietary supplements (Supplements).